Hydrocortison Panpharma

Hydrocortison Panpharma contains hydrocortisone hydrogen succinate, a glucocorticoid administered intravenously. It is a prescription‑only product marketed in the European Union. The formulation provides rapid systemic glucocorticoid activity for conditions requiring immediate anti‑inflammatory or immunosuppressive therapy. It is supplied without a specified strength in this description, and is used under medical supervision.

Hydrocortison Panpharma is indicated for several acute medical situations where swift glucocorticoid effect is needed.

- Replacement therapy in adrenal insufficiency (e.g., Addison’s disease or secondary adrenal failure). - Management of acute adrenal crisis or shock. - Treatment of severe systemic inflammatory or allergic reactions, such as anaphylaxis. - Adjunctive therapy in severe asthma exacerbations or other life‑threatening inflammatory conditions. - Supportive care in septic shock when cortisol response is inadequate.

Adverse reactions to Hydrocortison Panpharma can vary from mild and transient to rare but serious events.

Common: - Transient hyperglycemia or elevated blood glucose. - Mild electrolyte disturbances such as sodium retention or potassium loss. - Headache, dizziness, or flushing. - Local irritation at the infusion site. - Nausea or vomiting. - Insomnia or mood changes. - Mild muscle weakness.

Serious: - Severe infection or sepsis due to immunosuppression. - Acute adrenal crisis on abrupt discontinuation. - Allergic reactions including rash, urticaria, or anaphylaxis. - Psychiatric disturbances such as psychosis or severe mood swings. - Osteonecrosis of the femoral head (rare).

When prescribing Hydrocortison Panpharma, clinicians should evaluate several safety considerations to minimize risk.

- Assess for active infections; glucocorticoids can worsen bacterial, viral, or fungal diseases. - Monitor blood glucose and electrolytes, especially in diabetic or renal‑impaired patients. - Use the lowest effective dose and limit duration to reduce adrenal suppression. - Evaluate for a history of peptic ulcer disease or gastrointestinal bleeding. - Consider pregnancy and lactation status; safety data are limited. - Review concomitant medications that may increase bleeding risk or affect cortisol metabolism. - Adjust dosage in patients with hepatic impairment, as metabolism may be altered.

Hydrocortison Panpharma may interact with other agents that influence cortisol metabolism or immune function.

Avoid: - Strong CYP3A4 inducers such as rifampin, phenytoin, or carbamazepine, which can reduce glucocorticoid levels. - Live vaccines, because immunosuppression may diminish vaccine efficacy and increase infection risk.

Use with caution: - Anticoagulants (e.g., warfarin) due to potential enhancement of anticoagulant effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) because of additive risk of gastrointestinal ulceration. - Diuretics that may exacerbate electrolyte imbalances. - Antidiabetic agents, as glucocorticoids can raise blood glucose requiring dose adjustment.